{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:06Z","timestamp":1793346606782,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"F.\u00a0Hoffmann-La Roche Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02845-6","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T15:01:26Z","timestamp":1714921286000},"page":"2414-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type\u00a01 Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"41","author":[{"given":"Christos","family":"Kokaliaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alexander","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Simone","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"issue":"1","key":"2845_CR1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2845_CR2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"11","key":"2845_CR3","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96(11):6307\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"56","key":"2845_CR4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE. International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2(56):423\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"2845_CR5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.braindev.2017.04.018","volume":"39","author":"K Kaneko","year":"2017","unstructured":"Kaneko K, Arakawa R, Urano M, Aoki R, Saiito K. Relationships between long-term observations of motor milestones and genotype analysis results in childhood-onset Japanese spinal muscular atrophy patients. Brain Dev. 2017;39(9):763\u201373.","journal-title":"Brain Dev"},{"issue":"4","key":"2845_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman RI, Stam M, Gijzen M, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry. 2017;88(4):365\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2845_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13023-021-02015-9","volume":"16","author":"R De Amicis","year":"2021","unstructured":"De Amicis R, Baranello G, Foppiani A, et al. Growth patterns in children with spinal muscular atrophy. Orphanet J Rare Dis. 2021;16(1):375.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2845_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JND-190465","volume":"7","author":"AMB van der Heul","year":"2020","unstructured":"van der Heul AMB, Cuppen I, Wadman RI, et al. Feeding and swallowing problems in infants with spinal muscular atrophy type\u00a01: an observational study. J Neuromuscul Dis. 2020;7(3):323\u201330.","journal-title":"J Neuromuscul Dis"},{"key":"2845_CR9","volume":"130","author":"YA Choi","year":"2020","unstructured":"Choi YA, Suh DI, Chae JH, Shin HI. Trajectory of change in the swallowing status in spinal muscular atrophy type\u00a0I. Int J Pediatr Otorhinolaryngol. 2020;130: 109818.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"2845_CR10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2845_CR11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323.","journal-title":"Arch Neurol"},{"issue":"9","key":"2845_CR12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type\u00a0I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"key":"2845_CR13","unstructured":"Burr P, Reddivari AKR. Spinal muscle atrophy. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560687\/. Accessed Feb 2024."},{"issue":"4","key":"2845_CR14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4187\/respcare.03584","volume":"60","author":"JR Bach","year":"2015","unstructured":"Bach JR, Sinquee DM, Saporito LR, Botticello AM. Efficacy of mechanical insufflation-exsufflation in extubating unweanable subjects with restrictive pulmonary disorders. Respir Care. 2015;60(4):477\u201383.","journal-title":"Respir Care"},{"issue":"4","key":"2845_CR15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/pai.2009.0002","volume":"22","author":"JR Bach","year":"2009","unstructured":"Bach JR, Reyna M, Hon A. Spinal muscular atrophy type\u00a01: prolongation of survival by noninvasive respiratory aids. Pediatr Asthma Allergy Immunol. 2009;22(4):151\u201362.","journal-title":"Pediatr Asthma Allergy Immunol"},{"key":"2845_CR16","unstructured":"Biogen. SPINRAZA\u00ae (nusinersen) [package insert] 2020. https:\/\/www.spinraza.com\/PI. Accessed Feb 2024."},{"key":"2845_CR17","unstructured":"Biogen. SPINRAZA\u00ae (nusinersen) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf. Accessed Feb 2024."},{"key":"2845_CR18","unstructured":"Roche. EVRYSDI\u00ae (risdiplam) prescribing information 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf. Accessed Feb 2024."},{"key":"2845_CR19","unstructured":"Roche. EVRYSDI\u00ae (risdiplam) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf. Accessed Feb 2024."},{"key":"2845_CR20","unstructured":"Novartis. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) [package insert] Bannockburn, IL2019. https:\/\/www.fda.gov\/media\/126109\/download. Accessed Feb 2024."},{"key":"2845_CR21","unstructured":"Novartis. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) summary of product characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed Feb 2024."},{"issue":"9","key":"2845_CR22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","volume":"33","author":"BT Darras","year":"2019","unstructured":"Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919\u201332.","journal-title":"CNS Drugs"},{"issue":"12","key":"2845_CR23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Beldzinska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type\u00a01 spinal muscular atrophy (FIREFISH part\u00a02): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2845_CR24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type\u00a01 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"2845_CR25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type\u00a01 (STR1VE-EU): an open-label, single-arm, multicentre, phase\u00a03 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2845_CR26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase\u00a03 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2845_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014;17(2):157\u201373.","journal-title":"Value Health"},{"key":"2845_CR28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cpt.2247","volume":"110","author":"G Baranello","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M, et al. Prognostic factors and treatment-effect modifiers in spinal muscular atrophy. Clin Pharmacol Ther. 2021;110:1435\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2845_CR29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2845_CR30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"1","key":"2845_CR31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-020-01124-6","volume":"20","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Ni W. Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes. BMC Med Res Methodol. 2020;20(1):241.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"2845_CR32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2021-0216","volume":"11","author":"V Aponte Ribero","year":"2022","unstructured":"Aponte Ribero V, Daigl M, Marti Y, et al. How does risdiplam compare with other treatments for types 1\u20133 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022;11(5):347\u201370.","journal-title":"J Comp Eff Res"},{"issue":"12","key":"2845_CR33","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jval.2022.09.212","volume":"25","author":"Y Marti-Gil","year":"2022","unstructured":"Marti-Gil Y, Aponte Ribero V, Gorni K, et al. CO135 Matching-adjusted indirect comparison of risdiplam versus nusinersen in type\u00a01 spinal muscular atrophy: 2-year update. Value Health. 2022;25(12):S44.","journal-title":"Value Health"},{"key":"2845_CR34","unstructured":"ClinicalTrials.gov. NCT02913482:\u00a0a study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type\u00a01 spinal muscular atrophy (FIREFISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02913482. Accessed Feb 2024."},{"issue":"18","key":"2845_CR35","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"key":"2845_CR36","unstructured":"ClinicalTrials.gov. NCT02594124: a study for participants with spinal muscular atrophy (SMA) who previously participated in nusinersen (ISIS 396443) investigational studies. (SHINE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02594124. Accessed Feb 2024."},{"key":"2845_CR37","unstructured":"Biogen. German benefit assessment dossier 2020. https:\/\/www.g-ba.de\/downloads\/92-975-4215\/2020-12-01_Modul4A.4_Nusinersen.pdf. Accessed Feb 2024."},{"key":"2845_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"2845_CR39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311.","journal-title":"Med Decis Mak"},{"key":"2845_CR40","unstructured":"Phillippo AE, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submissions to NICE NICE2016. Updated December. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed Feb 2024."},{"issue":"12","key":"2845_CR41","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s40273-019-00831-3","volume":"37","author":"V Kapetanakis","year":"2019","unstructured":"Kapetanakis V, Prawitz T, Schlichting M, et al. Assessment-schedule matching in unanchored indirect treatment comparisons of progression-free survival in cancer studies. Pharmacoeconomics. 2019;37(12):1537\u201351.","journal-title":"Pharmacoeconomics"},{"key":"2845_CR42","unstructured":"Hawkins N, Gorni K, Daigl M, et al. Matching-adjusted indirect comparison of risdiplam versus nusinersen in type\u00a01 spinal muscular atrophy: 2-year update. 17th international congress on neuromuscular diseases, 5\u20139 July 2022. Brussels, Belgium."},{"key":"2845_CR43","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6:e00447.","journal-title":"Pharmacol Res Perspect"},{"issue":"15","key":"2845_CR44","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"15","key":"2845_CR45","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type\u00a0III SMA mouse model. Genes Dev. 2010;24(15):1634\u201344.","journal-title":"Genes Dev"},{"issue":"1","key":"2845_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-020-02461-2","volume":"18","author":"JM Sullivan","year":"2020","unstructured":"Sullivan JM, Mazur C, Wolf DA, et al. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system. J Transl Med. 2020;18(1):309.","journal-title":"J Transl Med"},{"issue":"11","key":"2845_CR47","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"D Ramos","year":"2019","unstructured":"Ramos D, d\u2019Ydewalle C, Gabbeta V, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest. 2019;129(11):4817\u201331.","journal-title":"J Clin Invest"},{"key":"2845_CR48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18\u00a0months of age. J Pediatr. 1999;135:153\u201361.","journal-title":"J Pediatr"},{"issue":"3","key":"2845_CR49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, et al. The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155\u201361.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"2845_CR50","first-page":"1253","volume":"93","author":"L Maggi","year":"2022","unstructured":"Maggi L, Bello L, Bonanno S, et al. Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease. J Neurol Neurosurg Psychiatry. 2022;93(12):1253\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2845_CR51","first-page":"E41","volume":"63","author":"M Ar Rochmah","year":"2017","unstructured":"Ar Rochmah M, Shima A, Harahap NIF, et al. Gender effects on the clinical phenotype in Japanese patients with spinal muscular atrophy. Kobe J Med Sci. 2017;63(2):E41\u20134.","journal-title":"Kobe J Med Sci"},{"key":"2845_CR52","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1017\/cjn.2019.160","volume":"46","author":"RS Finkel","year":"2019","unstructured":"Finkel RS, Dabbous O, Arjunji R, et al. P.060 time to treatment effect in spinal muscular atrophy type\u00a01 (SMA1): an indirect comparison of treatments. Can J Neurol Sci. 2019;46:S30.","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"2845_CR53","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","volume":"40","author":"T Jiang","year":"2023","unstructured":"Jiang T, Youn B, Paradis AD, Beckerman R, Barnieh L, Johnson NB. A critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy. Adv Ther. 2023;40(7):2985\u20133005.","journal-title":"Adv Ther"},{"key":"2845_CR54","doi-asserted-by":"crossref","first-page":"S709","DOI":"10.1016\/j.jval.2020.08.1845","volume":"23","author":"S Liao","year":"2020","unstructured":"Liao S, Bohn J, de Moor C, Xaplanteris X, Farwell W, Padaris A. PR109 a cautionary tale for indirect treatment comparisons: an example from infantile-onset spinal muscular atrophy. Value Health. 2020;23:S709.","journal-title":"Value Health"},{"key":"2845_CR55","unstructured":"National Institute for Health and Care Excellence. Risdiplam for treating spinal muscular atrophy. Technology appraisal guidance [TA755]. https:\/\/www.nice.org.uk\/guidance\/ta755. Accessed Feb 2024."},{"issue":"8","key":"2845_CR56","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase\u00a02 randomized clinical trial. JAMA Neurol. 2020;77(8):982\u201391.","journal-title":"JAMA Neurol"},{"key":"2845_CR57","unstructured":"US Food and Drug Administration. Clinical review: viltolarsen 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212154Orig1s000MedR.pdf. Accessed Feb 2024."},{"issue":"2","key":"2845_CR58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257\u201371.","journal-title":"Ann Neurol"},{"key":"2845_CR59","unstructured":"US Food and Drug Administration. Clinical review: eteplirsen 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_redacted.pdf. Accessed Feb 2024."},{"key":"2845_CR60","doi-asserted-by":"crossref","first-page":"104551","DOI":"10.1016\/j.msard.2023.104551","volume":"71","author":"E Swallow","year":"2023","unstructured":"Swallow E, Pham T, Patterson-Lomba O, et al. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: a matching-adjusted indirect comparison. Mult Scler Relat Disord. 2023;71:104551.","journal-title":"Mult Scler Relat Disord"},{"key":"2845_CR61","unstructured":"US Food and Drug Administration. September 7, 2022: Meeting of the peripheral and central nervous system drugs advisory committee meeting announcement 2022. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-7-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting. Accessed Feb 2024."},{"key":"2845_CR62","unstructured":"European Medicines Agency. Assessment report: Kymriah 2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kymriah-epar-public-assessment-report_en.pdf. Accessed Feb 2024."},{"key":"2845_CR63","doi-asserted-by":"crossref","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. EVRYSDI (risdiplam) 2021. https:\/\/www.has-sante.fr\/jcms\/p_3289078\/fr\/evrysdi-0-75-mg\/ml-risdiplam#videotoc_1_1. Accessed Feb 2024.","DOI":"10.51731\/cjht.2021.185"},{"key":"2845_CR64","unstructured":"Australian Government, Department of Health and Aged Care. RISDIPLAM, Powder for oral solution 0.75\u00a0mg per 1mL, 80 mL, Evrysdi\u00ae, Roche Products Pty Ltd 2021. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2021-03\/files\/risdiplam-psd-mar-2021.pdf. Accessed Feb 2024."},{"key":"2845_CR65","unstructured":"ClinicalTrials.gov. NCT02193074: A study to assess the efficacy and safety of ISIS-SMNRx in infants with spinal muscular atrophy (ENDEAR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193074. Accessed Feb 2024."},{"issue":"5","key":"2845_CR66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, et al. Risdiplam-treated infants with type\u00a01 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"2845_CR67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349.","journal-title":"J Child Neurol"},{"issue":"2","key":"2845_CR68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part\u00a01: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2845_CR69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part\u00a02: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02845-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:27:28Z","timestamp":1716888448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02845-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02845-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SLR and data extraction were conducted by Bridge Medical Consulting Ltd., London, UK and funded by F.\u00a0Hoffmann-La Roche Ltd., Basel, Switzerland. ITC analyses were designed by Visible Analytics, UK, funded by F.\u00a0Hoffmann-La Roche Ltd. Christos Kokaliaris and Julian Nam are employees of F.\u00a0Hoffmann-La Roche Ltd. Julian Nam owns stocks in Roche. Rachel Evans is a former employee of Visible Analytics Ltd., which designed the analysis and received consultancy fees and expenses from F.\u00a0Hoffmann-La Roche Ltd. Neil Hawkins and David Alexander Scott are partners\/employees of Visible Analytics Ltd., which designed the analysis and received consultancy fees and expenses from F.\u00a0Hoffmann-La Roche Ltd. Anadi Mahajan is an employee of Bridge Medical Consulting Ltd., which conducted this SLR and received consultancy fees and expenses from F.\u00a0Hoffmann-La Roche Ltd. C Simone Sutherland was employed by F.\u00a0Hoffmann-La Roche Ltd and owns stocks in Roche. Gautam Sajeev is an employee of Analysis Group, Inc. which received consulting fees from Genentech Inc. (a member of the Roche group) for this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study did not require ethical approval as data were obtained from published studies. FIREFISH and ENDEAR received institutional review board approval and were conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained for patient participation in these studies. The data published in this article is owned by F.\u00a0Hoffmann-La Roche. Roche has the necessary permissions to share with readers upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}